A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

NCT03886662 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: LB-100

Sponsor

Lixte Biotechnology Holdings, Inc.